Practice guidelines for pharmacists: The pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs

Documenti analoghi

• Toxicity profiles of traditional disease modifying antirheumatic drugs for rheumatoid arthritis
  di: Aletaha, D, et al.
  Pubblicazione: (2003)
• Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis
  di: Emery, Paul, et al.
  Pubblicazione: (2013)
• Premise: traditional disease-modifying antirheumatic drugs are less effective and safe than targeted therapy with biologic response modifiers in rheumatoid arthritis
  di: Fleischmann, R
  Pubblicazione: (2003)
• Rationales for discontinuation of disease-modifying antirheumatic drugs, biologic agents, and tofacitinib in rheumatoid arthritis
  di: Yu. V. Muraviev, et al.
  Pubblicazione: (2018-12-01)
• EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
  di: Smolen, Josef S, et al.
  Pubblicazione: (2010)